Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE versus METICORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE versus METICORTEN.
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE vs METICORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone sodium phosphate is a corticosteroid with potent anti-inflammatory and immunosuppressant properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of pro-inflammatory cytokines, inhibition of phospholipase A2, and reduction of inflammatory mediators like prostaglandins and leukotrienes.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression and suppressing inflammation, immune response, and adrenal function.
0.5-24 mg/day IV or IM in divided doses every 6-12 hours; acute conditions: 4-20 mg IV initially, then 2-4 mg every 4-6 hours.
5-60 mg orally once daily, depending on condition; for acute exacerbations, up to 250 mg IV every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; clinical context: biological effects persist >24 hours due to prolonged receptor binding.
Following oral or IV administration, the terminal elimination half-life of total prednisolone (active form) is 2.1–3.5 hours in adults with normal hepatic function. In hepatic impairment, half-life may be prolonged (up to 6–8 hours), necessitating dose adjustment.
Primarily renal (approximately 65-80% as free steroid and glucuronide conjugates); minor biliary/fecal elimination (10-15%).
Primarily renal: approximately 80% as inactive metabolites (conjugated and oxidized forms) and <5% as unchanged prednisolone. Biliary/fecal excretion accounts for about 10-15% of the dose.
Category D/X
Category C
Corticosteroid
Corticosteroid